Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.

Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.

BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.

Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.

European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.

Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.

Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.

GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.